40 Participants Needed

Atomic Magnetometer Brain Imaging for Epilepsy

LL
IB
Overseen ByIsabelle Buard, PhD
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: University of Colorado, Denver
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

What is the purpose of this trial?

This study is being done to help scientists learn about the use of a device called an atomic magnetometer. The device uses sensors called optically-pumped magnetometers (OPM) which function at room temperature. This research will compare the non-invasive brain imaging application of the OPM sensors to the present SQUID-based cryogenic sensor technique used in conventional Magnetoencephalography (MEG). This study is being conducted in conjunction with the University of Colorado Boulder's Mechanical Engineering Department.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the study team or your doctor.

What data supports the effectiveness of the treatment OPM sensors, Optically Pumped Magnetometers, Room Temperature Atomic Magnetometers, SQUID sensors, Superconducting Quantum Interference Devices for epilepsy?

Research shows that optically pumped magnetometers (OPMs) can detect epileptic brain activity with a better signal-to-noise ratio than traditional SQUID sensors, making them a promising tool for epilepsy diagnosis and management. OPMs are also wearable and more affordable, allowing for easier and more widespread use in clinical settings, especially for children and patients with movement during seizures.12345

Is the use of atomic magnetometers for brain imaging safe for humans?

Research on optically pumped magnetometers (OPMs) for brain imaging, such as magnetoencephalography (MEG), suggests they are safe for human use. These devices are non-invasive, operate at room temperature, and do not require the cryogenic cooling needed for traditional SQUID sensors, reducing potential risks associated with extreme temperatures.678910

How does the Atomic Magnetometer Brain Imaging treatment for epilepsy differ from other treatments?

This treatment uses optically pumped atomic magnetometers (OPAMs) to detect magnetic fields in the brain, offering a non-invasive and room-temperature alternative to traditional superconducting devices that require expensive cryogenic cooling. It provides high-resolution imaging of epileptic events, similar in size and flexibility to EEG electrodes, making it more practical for long-term monitoring of seizures.5691112

Eligibility Criteria

This trial is for adults aged 18-70 with epilepsy, referred through the clinical MEG program. It's not for pregnant women, those unable to consent, people with neurological disorders other than epilepsy or who can't lie still during recording, and anyone with metal implants that could interfere with sensor readings.

Inclusion Criteria

I am between 18 and 70 years old.
I am between 18 and 70 years old and was referred through the clinical MEG program.

Exclusion Criteria

You have a history of conditions that affect the brain and nervous system, like epilepsy or Parkinson's disease.
I cannot give informed consent on my own.
I cannot stay still for long periods.
See 2 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Device Testing

Participants undergo non-invasive brain imaging using OPM and SQUID sensors to compare their effectiveness

1 day
1 visit (in-person)

Follow-up

Participants are monitored for any adverse effects and the effectiveness of the imaging techniques is evaluated

4 weeks

Treatment Details

Interventions

  • OPM sensors
  • SQUID sensors
Trial OverviewThe study tests a new brain imaging device using OPM sensors against the traditional SQUID sensors in Magnetoencephalography (MEG). The goal is to see if OPMs offer a non-invasive way to monitor brain activity at room temperature effectively.
Participant Groups
2Treatment groups
Experimental Treatment
Group I: healthy adultsExperimental Treatment2 Interventions
Any adult, who is at least eighteen (18-70) years old.
Group II: Patients with intractable epilepsyExperimental Treatment2 Interventions
Any clinical patient referred to us via the clinical MEG program, and who is at least eighteen (18-70) years old.

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of Colorado, Denver

Lead Sponsor

Trials
1,842
Recruited
3,028,000+

University of Colorado, Boulder

Collaborator

Trials
128
Recruited
29,600+

Findings from Research

OPM-MEG is a novel, cost-effective wearable technology that can accurately record brain activity in real-time, making it suitable for both children and adults, especially in evaluating epilepsy without the need for sedation.
Unlike traditional SQUID-MEG, OPM-MEG is resistant to head motion, which enhances its usability in clinical settings, particularly for monitoring severe childhood epilepsies and potentially improving long-term epilepsy management.
Wearable OPM-MEG: A changing landscape for epilepsy.Pedersen, M., Abbott, DF., Jackson, GD.[2023]
Optically Pumped Magnetometers (OPMs) placed directly on the scalp significantly improve the signal-to-noise ratio (SNR) for detecting brain activity, making them particularly effective for diagnosing epilepsy in both adults and children, especially in cases with deep brain sources.
In a study involving seven patients, OPMs demonstrated comparable performance to traditional cryogen-based MEG systems, with the added benefit of being wearable, allowing for seizure recordings in patients with movement, which could enhance the evaluation and diagnosis of epilepsy.
Non-invasive measurements of ictal and interictal epileptiform activity using optically pumped magnetometers.Hillebrand, A., Holmes, N., Sijsma, N., et al.[2023]
Magnetoencephalography (MEG) is a valuable non-invasive tool that can significantly improve the identification of surgical candidates and guide pre-surgical planning for patients with focal, medication-resistant epilepsy, yet it is underutilized in many epilepsy centers in the USA.
While advancements in sensor technology, particularly optically pumped magnetometers (OPMs), hold promise for making MEG more accessible and affordable, current OPM devices are not yet ready for clinical use, meaning that the field will likely continue to rely on existing SQUID technology for the next decade.
Role of optically pumped magnetometers in presurgical epilepsy evaluation: Commentary of the American Clinical Magnetoencephalography Society.Bagiฤ‡, AI., Bowyer, SM., Burgess, RC., et al.[2023]

References

Wearable OPM-MEG: A changing landscape for epilepsy. [2023]
Non-invasive measurements of ictal and interictal epileptiform activity using optically pumped magnetometers. [2023]
Role of optically pumped magnetometers in presurgical epilepsy evaluation: Commentary of the American Clinical Magnetoencephalography Society. [2023]
Helium optically pumped magnetometers can detect epileptic abnormalities as well as SQUIDs as shown by intracerebral recordings. [2023]
Magnetoencephalography of epilepsy with a microfabricated atomic magnetrode. [2022]
Compensation System for Biomagnetic Measurements with Optically Pumped Magnetometers inside a Magnetically Shielded Room. [2021]
Non-Invasive Functional-Brain-Imaging with an OPM-based Magnetoencephalography System. [2022]
Precision magnetic field modelling and control for wearable magnetoencephalography. [2022]
Remote detected Low-Field MRI using an optically pumped atomic magnetometer combined with a liquid cooled pre-polarization coil. [2018]
Performance Analysis of Optically Pumped 4He Magnetometers vs. Conventional SQUIDs: From Adult to Infant Head Models. [2022]
11.United Statespubmed.ncbi.nlm.nih.gov
Optical multichannel room temperature magnetic field imaging system for clinical application. [2022]
Non-invasive detection of animal nerve impulses with an atomic magnetometer operating near quantum limited sensitivity. [2023]